Today marks an incredibly important milestone for the Algorics team: OmniComm Systems and Algorics have signed a letter of intent, under which OmniComm will acquire certain assets and assume certain liabilities of Algorics. By combining forces, the companies expect increased operating efficiency, strengthened traction in the maturing risk-based approach solution area, new marketing opportunities and an expanded portfolio of electronic data capture (EDC) solutions for the global clinical trials industry.
We’ve been partnering with OmniComm for the last two and a half years. The companies are a very good fit culturally, with a high compatibility of technologies and shared vision for clinical trials innovationWe have developed algorithms and software to address the increasing demands from global regulatory bodies for reduced regulatory risk, improved quality and compliance with real-time insight. Joining OmniComm will accelerate our goal of becoming the best-in-class solution for risk-based monitoring and clinical data analytics. We look forward to bringing additional competitive advantages to OmniComm’s customers by delivering end-to-end RBM solutions and specialized data analytics expertise.
This excellent company news adds another success to a year which has seen myself, our hard-working and innovative team and our product innovation recognised within the clinical research & technology industry; named in the PharmaVOICE 100 and as a finalist in the Scrip Awards in the ‘Best Technological Development in Clinical Trials – Sponsor-focused’ category. These achievements would not have been possible without the dedication of the Algorics team, the direction of our expert industry advisory board and the support from our customers and technology partners. We will be celebrating this milestone news and look forward to sharing our future combined successes with you. For now, a heart-felt thank you from myself and the Algorics executive team, Abby Abraham and Rob Nichols, for all your support!